<DOC>
	<DOCNO>NCT00635128</DOCNO>
	<brief_summary>Subjects age 9 13 year participate 711866/001 study 5 year ago evaluate immune persistence receive combine dTpa-IPV booster dose evaluate term immunogenicity , safety reactogenicity .</brief_summary>
	<brief_title>Safety Immunogenicity Booster Dose GSK Biological 's Boostrix-Polio Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol enrol study . A male female subject receive booster vaccination dTpaIPV dTpa + IPV study 711866/001 . Healthy subject establish medical history clinical examination enter study . Females childbearing potential time study entry must negative pregnancy test prior administration dose vaccine require abstinent use adequate contraceptive precaution one month prior vaccination . Subjects require agree continue precaution two month vaccination . Written inform consent obtain parents/ guardian subject ; assent subject himself/herself also request whenever possible . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede booster dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior booster dose . Administration vaccine foreseen study protocol within 30 day prior vaccination , plan administration study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Previous booster vaccination tetanus , diphtheria , pertussis , poliomyelitis since booster dose receive study 711866/001 . History diphtheria , tetanus , pertussis , poliomyelitis disease . Any confirm suspected immunosuppressive immunodeficiency condition , base medical history physical examination . History allergic disease reaction likely exacerbate component vaccine . Administration immunoglobulin and/or blood product within three month precede booster dose plan administration study period . Occurrence transient thrombocytopenia neurological complication follow early immunisation diphtheria and/or tetanus . Occurrence follow adverse event ( AEs ) previous administration DTP vaccine : hypersensitivity reaction component vaccine , encephalopathy unknown aetiology occur within 7 day follow previous vaccination pertussiscontaining vaccine , fever ≥ 40°C within 48 hour vaccination due another identifiable cause , collapse shocklike state within 48 hour vaccination Persistent , severe , inconsolable scream cry last &gt; 3 hour occur within 48 hour receipt previous dose DTP vaccine convulsion without fever , occur within 3 day vaccination . Acute disease time enrolment . Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>vaccine</keyword>
	<keyword>DTP</keyword>
	<keyword>Poliomyelitis</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Booster</keyword>
	<keyword>Tetanus</keyword>
</DOC>